A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial

(2017) Loic Verlingue et al.   EUROPEAN JOURNAL OF CANCER

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Cholangiocarcinoma — evolving concepts and therapeutic strategies

(2017) Sumera Rizvi et al.   Nature Reviews Clinical Oncology

A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma

(2017) Ting-Ting Pan et al.   Oncology Letters

New Horizons for Precision Medicine in Biliary Tract Cancers

(2017) Juan W. Valle et al.   Cancer Discovery

Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database

(2016) Kaelan J. Yao et al.   BMC GASTROENTEROLOGY

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise

(2016) Supriya K. Saha et al.   ONCOLOGIST

Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma

(2015) A. Moeini et al.   CLINICAL CANCER RESEARCH

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

(2015) Juan W Valle et al.   LANCET ONCOLOGY

Genomic spectra of biliary tract cancer

(2015) Hiromi Nakamura et al.   NATURE GENETICS

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma

(2014) A B El-Khoueiry et al.   BRITISH JOURNAL OF CANCER

Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway

(2014) Maolan Li et al.   NATURE GENETICS

Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma

(2014) Mitesh J. Borad et al.   PLoS Genetics

Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma

(2013) Sumera Rizvi et al.   GASTROENTEROLOGY

Changing pattern of epidemiology in intrahepatic cholangiocarcinoma

(2013) Basile Njei   HEPATOLOGY

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

(2013) Roberta Schmieder et al.   INTERNATIONAL JOURNAL OF CANCER

Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model

(2013) L. Abou-Elkacem et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study

(2011) Jun Ho Yi et al.   EUROPEAN JOURNAL OF CANCER

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

(2011) Anthony B. El-Khoueiry et al.   INVESTIGATIONAL NEW DRUGS

A Phase I–II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas

(2010) Ulrik Lassen et al.   ACTA ONCOLOGICA

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study

(2010) Sam J. Lubner et al.   JOURNAL OF CLINICAL ONCOLOGY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract Cancer

(2009) Suee Lee et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

(2009) D Yoshikawa et al.   BRITISH JOURNAL OF CANCER

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

(2009) C Bengala et al.   BRITISH JOURNAL OF CANCER

Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial

(2009) Joung-Soon Jang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II Trial of S-1 in Combination with Oxaliplatin in Previously Untreated Patients with Recurrent or Inoperable Biliary Tract Cancer

(2008) Sung Yong Oh et al.   CHEMOTHERAPY